Background: Sodium-glucose cotransporter-2 inhibitors promote glycosuria, resulting in possible effects on calcium, phosphate, and vitamin D homeostasis. Canagliflozin is associated with decreased bone mineral density and a potential increased risk for fracture.
S
odium-glucose cotransporter-2 (SGLT2) inhibitors decrease plasma glucose levels by inhibiting reabsorption of glucose at the proximal tubule and lowering the renal threshold for glucose excretion (1) . The resulting osmotic diuresis may also affect calcium, phosphate, and vitamin D homeostasis (2) . Canagliflozin, unlike other SGLT2 inhibitors, is associated with decreased bone mineral density (3, 4) . Patients with diabetes mellitus are at increased risk for fractures, and canagliflozin may exacerbate this risk (5, 6) .
A recent systematic review of clinical trial data suggested that canagliflozin was not associated with increased risk for fractures (7). However, most trials included in the review were small or enrolled patients with relatively mild diabetes. Among the included trials, the mean age of patients was about 50 years, most were not prescribed insulin, and diabetesrelated complications were uncommon (7).
The CANVAS (CANagliflozin cardioVascular Assessment Study) Program integrated data from 2 cardiovascular outcome trials: a cardiovascular safety study (CANVAS) and a cardiovascular safety study that also assessed renal outcomes (CANVAS-R) (8, 9) . Across these trials, which enrolled 10 142 total patients, the mean age was 63 years, nearly two thirds of patients had cardiovascular disease, half were prescribed insulin, and most had diabetes for approximately 13 years. CANVAS found increased risk for fracture among patients randomly assigned to canagliflozin compared with placebo (hazard ratio [HR], 1.56 [95% CI, 1.18 to 2.06] ). Fractures occurred as early as 12 weeks after treatment and mostly affected the upper limbs (for example, humerus or radius) or the lower limbs (for example, hip or foot) (9). In CANVAS-R, patients who received canagliflozin did not have greater risk for fracture than placebo recipients (HR, 0.76 [CI, 0.52 to 1.12] ).
These conflicting results raise challenges in counseling patients prescribed canagliflozin about the risk for fracture. The primary objective of this study was to assess fracture risk in the radius, ulna, humerus, hip, or pelvis among patients with diabetes who were newly prescribed canagliflozin in routine care.
databases: the deidentified Optum Clinformatics Data Mart ("Optum") and IBM MarketScan ("MarketScan"). Both capture patient demographic characteristics and longitudinal, individual-level data on health care use, inpatient and outpatient diagnostic tests and procedures, and pharmacy dispensing of drugs for more than 70 million persons in the United States. The Brigham and Women's Hospital Institutional Review Board provided ethics approval, and a valid data use agreement was in place for both databases.
Study Cohort
We compared adults (aged ≥18 years) with type 2 diabetes mellitus who were newly prescribed canagliflozin or a glucagon-like peptide-1 (GLP-1) agonist between 29 March 2013 (the date of approval of canagliflozin in the United States) and 1 October 2015 (the date of the last available data). Patients with type 2 diabetes were identified using International Classification of Diseases, Ninth Revision codes (Appendix Table 1 , available at Annals.org). New users of canagliflozin or GLP-1 agonists were defined as those without a prescription in the preceding 180 days (see Appendix Table 2 for the list of eligibility criteria and Appendix Figure 1 [both available at Annals.org]). Because GLP-1 agonists were approved before SGLT2 inhibitors, some patients whom we identified as new users of GLP-1 agonists may have received them before the cohort entry date, discontinued use, and subsequently resumed use during our study period after a washout period of 180 days without a filled prescription for canagliflozin or a GLP-1 agonist. The cohort entry date was the date of the first prescription during our study period.
We chose GLP-1 agonists as the comparator because they are a second-line treatment for diabetessimilar to SGLT2 inhibitors-and are not associated with increased risk for fracture (10, 11). We did not include other SGLT2 inhibitors because data were limited. We decided against including dipeptidyl peptidase-4 inhibitors as another comparator because they were used in patients who were an average of 10 years older than users of SGLT2 inhibitors (data not shown), and age is among the strongest risk factors for fracture.
Patients receiving both canagliflozin and a GLP-1 agonist on the cohort entry date were excluded, as were those with any of the following in the 180 days before cohort entry: insufficient baseline health care data (<180 days); HIV; end-stage renal disease (including prior renal transplant); hospitalization for hypoglycemia; cancer; previous fracture of the hip, pelvis, radius, ulna, or humerus; or type 1 diabetes.
Follow-up
Follow-up began on the day after cohort entry and continued until the end of the study period (1 October 2015) , the end of continuous health plan enrollment, occurrence of a study outcome, discontinuation of use of the initial medication (or a switch to or addition of a comparator medication), or death. Medication use was considered to be discontinued if 60 days elapsed after expiration of the last prescription's supply without the prescription being refilled.
Outcomes
The primary outcome was a composite end point of pelvic fracture, hip fracture requiring surgery, humerus fracture requiring intervention (surgery, casting, or splinting), or radius or ulna fracture requiring intervention (Appendix Table 3 , available at Annals.org). Use of claims data to identify these fractures has been previously validated against hospital records and found to generally have a positive predictive value greater than 92% (12-14). We performed a post hoc analysis that excluded pathologic fractures or fractures related to high-impact trauma (Appendix Table 4 , available at Annals.org). Secondary outcomes included the primary outcome without intervention (for example, hip fracture without surgery), serious fall injury (15), severe hypoglycemia (positive predictive value, 89%) (16), and fractures at other sites reported in CANVAS (carpal, metacarpal, metatarsal, and ankle) (9, 17). Serious fall injury and severe hypoglycemia were included to help identify potential triggering events that might lead to fracture.
Covariates
Patient demographic characteristics were assessed during the 180 days before cohort entry. Data were collected on diagnoses and procedures recorded during health encounters for each patient and included information on chronic medical conditions (such as hypertension, coronary artery disease, or stroke), diabetes severity (for example, end-organ damage or insulin use), fracture risk (for example, osteoporosis or recent steroid use), health care use (for example, recent hospitalization or emergency department visit), prescriber information (for example, endocrinologist or general practitioner), diabetes medications (such as metformin), nondiabetes medications (such as bisphosphonates or antihypertensives), and proxies for frailty (such as use of a walker). The frailty indicators have been previously validated and are associated with subsequent death, disability, mobility impairment, and recurrent falls (18, 19) . All covariates were selected on the basis of previous studies and clinical experience (5, 20, 21) .
Statistical Analysis
Propensity score matching was used to adjust for confounding. The probability of initiating use of canagliflozin versus a GLP-1 agonist was calculated using a multivariable logistic regression model that contained all potential confounders at baseline except hemoglobin A 1c level, which was available for only about 35% of patients in Optum and 6% of those in MarketScan (mean values are shown in Table 1 ). There were no other missing data in our study. The estimated propensity score was used to match in a 1:1 ratio persons who initiated use of canagliflozin with those initiating use of GLP-1 agonists separately in each database. Nearestneighbor matching without replacement was performed using a caliper of 0.05 on the propensity score scale. The propensity score was reestimated for each subgroup analysis. Covariate balance within the matched cohorts was assessed by using standardized differences. A standardized difference of 0.1 or less indicated negligible differences between groups (22). GLP-1 = glucagon-like peptide-1; Z-drug = zolpidem or zaleplon. * Data are numbers (percentages) unless otherwise indicated. Differences in baseline characteristics were assessed using standardized differences within each database. All were <0.1 after propensity score matching. † Data were available for 35% of patients in Optum and 6% in MarketScan. ‡ Based on references 18 and 19.
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After matching, Cox proportional hazards models were used to estimate HRs and 95% CIs for the primary and secondary outcomes without further adjustments. Individual HRs were calculated separately in each database and then combined via a fixed-effects meta-analysis using inverse variance weighting (23). Kaplan-Meier plots with 95% CIs were generated to visualize risk for outcome events in both groups for each database.
Several predefined sensitivity and subgroup analyses were performed, including one in which exposure to the first-used medication was carried forward for 365 days without consideration of treatment discontinuation, switching, or augmentation (intention-to-treat analysis) and one restricted to patients older than 60 years (to understand the effect of age on fracture risk). To assess risk for fracture after longer exposure, we evaluated risk for the primary outcome in a subgroup of patients with at least 6 months of follow-up with the index medication and started follow-up at day 181. The statistical analysis was otherwise identical to that performed for the primary outcome. As a positive control, we assessed risk for a first episode of heart failure because previous randomized clinical trials have shown a reduction in heart failure with canagliflozin but not GLP-1 agonists (8). Analyses were conducted using the Aetion platform, which has been validated for a range of studies (24) and for predicting clinical trial findings (25, 26); R, version 3.4.2 (R Foundation for Statistical Computing); and Stata IC, version 14.2 (StataCorp) (Appendix Table 4 ).
Role of the Funding Source
This study was funded by internal resources in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital. The authors had complete control over the design, conduct, and analysis of the study and the decision to submit the manuscript for publication.
RESULTS

Study Population
We identified 194 581 total patients in Optum and MarketScan who met inclusion criteria (Appendix Figure 2, available at Annals.org). Among these, 92 779 were newly prescribed canagliflozin and 101 802 were newly prescribed a GLP-1 agonist (Appendix Table 5 , available at Annals.org). Across both data sets, canagliflozin was prescribed slightly more often in the second half of the study period, and patients were more likely to be male and were prescribed slightly more diabetes medications (for example, a dipeptidyl peptidase-4 inhibitor) but were less likely to be prescribed a diuretic or an opioid. Patients prescribed GLP-1 agonists were more likely to have kidney disease; be prescribed insulin, an antidepressant, or an anticonvulsant; or have a measure of frailty (Appendix Table 5 ). The remaining baseline characteristics, including hemoglobin A 1c level, glaucoma, cataracts, previous fall, osteoporosis, and recent bone mineral density testing, were well balanced (standardized differences <0.1) before propensity score matching.
After 1:1 propensity score matching, we obtained 23 458 pairs of patients newly prescribed canagliflozin or a GLP-1 agonist in Optum and 56 506 pairs newly prescribed either medication in MarketScan. Overall, mean age was approximately 55 years; 52% were male; and prevalence of metformin or insulin use at baseline was 57% and 27%, respectively. The major risk factors for fracture, such as osteoporosis, dementia, and frailty indicators, were rare in both groups ( Table 1 ). All covariates were well balanced, with standardized differences less than 0.1. Baseline hemoglobin A 1c levels were approximately 8.7% among patients prescribed a GLP-1 agonist and about 8.8% among those prescribed canagliflozin. The mean duration of follow-up was 34 weeks (SD, 27) ( Table 2 ). In CANVAS, increased fracture risk was apparent within 12 weeks of initiation of treatment with canagliflozin (8, 9).
Primary Outcome
In MarketScan, we observed 94 events (1.9 per 1000 person-years) of pelvic fracture; hip fracture requiring surgery; or humerus, radius, or ulna fracture requiring intervention among 66 237 unmatched patients who initiated use of canagliflozin compared with 106 events (2.4 per 1000 person-years) among 68 729 unmatched patients who initiated use of a GLP-1 agonist. In the propensity score-matched cohort, there were 84 events (2.1 per 1000 person-years) among 56 506 patients who initiated use of canagliflozin compared with 82 events (2.3 per 1000 person-years) among 56 506 patients who initiated use of a GLP-1 agonist. The propensity score-matched rate of the primary composite end point was similar between groups (HR, 0.92 [CI, 0.68 to 1.25] ).
In Optum, we observed 40 events (2.7 per 1000 person-years) of pelvic fracture; hip fracture requiring sur- Table 2 ).
The overall propensity score-matched rate of the primary outcome across both data sources did not indicate increased risk for fracture with canagliflozin (HR, 0.98 [CI, 0.75 to 1.26]). The cumulative incidence of fractures, pooled across both databases, between patients prescribed canagliflozin and those prescribed GLP-1 agonists is depicted in the Kaplan-Meier plot in the left panel of Figure 1 and is consistent with these findings. The Kaplan-Meier plots for each database showed similar patterns (Appendix Figure 3 , available at Annals.org). In our post hoc analysis that excluded pathologic fractures or fractures related to recent trauma, our primary outcome was essentially unchanged (HR, 0.90 [CI, 0.70 to 1.15]).
Sensitivity Analyses
When we carried forward exposure to the first-used medication for 365 days without considering treatment discontinuation in our intention-to-treat analysis, propensity score-matched results again showed no in- 
Secondary Outcomes
The propensity score-matched risk for the expanded primary outcome without intervention was similar for GLP-1 agonists and canagliflozin (MarketScan HR, 0.90 [CI, 0.73 Figure 1 and is consistent with these findings (Appendix Figure 4 , available at Annals.org).
Risk for fracture among patients with longer exposure and risks for severe fall injury and severe hypoglycemia were not increased with canagliflozin compared with GLP-1 agonists (Figure 2 ).
Validation Against a Known Causal Association
The propensity score-matched risk for a first heart failure episode was lower for patients prescribed canagliflozin ( 
DISCUSSION
Using data from 2 large U.S. health care databases, we found that the overall rate of fracture was similarly low Fracture Risk After Initiation of Use of Canagliflozin ORIGINAL RESEARCH among patients with type 2 diabetes who were treated with canagliflozin or GLP-1 agonists. Findings were robust across multiple sensitivity and subgroup analyses. Our study population is representative of a meaningful proportion of commercially insured patients with diabetes in the U.S. population.
Assessing risk for fracture among patients receiving new diabetes medications is important because patients with diabetes are prone to fractures (5, 20, 27) . Fractures can cause significant morbidity and mortality, with hip fracture associated with 1-year mortality of up to 60% (28). This may be particularly relevant for patients prescribed canagliflozin because of its effects on phosphate, calcium, vitamin D, and parathyroid hormone homeostasis (3, 29). Specifically, canagliflozin can have a net effect of increased serum phosphate levels, reduced serum 1,25-dihydroxyvitamin D levels, and reduced bone mineral density (3, 29). Despite biological mechanisms that suggest increased risk for fracture, our study did not detect increased risk with canagliflozin as used in routine care.
Our findings support those of 2 meta-analyses published before the CANVAS trials (7, 30). In the meta-analysis by Tang and colleagues, fracture with SGLT2 inhibitors was rare (323 events in 20 264 patients who received an SGLT2 inhibitor) and the overall odds of fracture was 1.02 (CI, 0.84 to 1.23), based on pooled results from 38 trials (30). These trials were evenly split among the 3 SGLT2 inhibitors, and 68% enrolled patients with an average age less than 60 years. The meta-analysis by Wu and colleagues, which was based on regulatory submissions and scientific reports, also found that canagliflozin was not associated with increased fracture risk (7). Both metaanalyses were primarily based on clinical trials of relatively young patients, which raises the question of whether only older patients might have increased risk. The results of the CANVAS studies may support this hypothesis.
The CANVAS trials included 10 142 participants randomly assigned to canagliflozin or placebo. Risks for low-trauma fracture (primary fracture outcome) and all fractures (secondary fracture outcome) were assessed for patients who received 1 or more doses of canagliflozin or placebo. In CANVAS (n = 4330), risk was higher with canagliflozin than placebo for low-trauma fracture (13 vs. 8 events per 1000 patient-years; HR, GLP-1 = glucagon-like peptide-1; HR = hazard ratio. * Includes patients with ≥6 mo of follow-up.
† Includes pelvis, hip, humerus, radius, ulna, carpal, metacarpal, metatarsal, and ankle.
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One difference between CANVAS and CANVAS-R was the proportion of Asian patients enrolled (18% vs. 8%, respectively). The meta-analysis by Tang and colleagues suggested that Asian persons who received an SGLT2 inhibitor may have had a 2-fold higher odds of fracture (odds ratio, 2.05 [CI, 0.86 to 4.87]) than those who did not. Thus, the discordant risks observed between CANVAS and CANVAS-R might be attributable to effect modification by race. We could not test this hypothesis because we did not have access to information on race.
Our study had a maximum follow-up of 142 weeks and a mean of 34 weeks. Therefore, the Kaplan-Meier curves showed increasing uncertainty after 1 year. However, in the CANVAS trial, increased risk for fracture was detected within 12 weeks of treatment initiation, so duration of follow-up alone probably does not explain our null findings. An alternate explanation might be lower baseline risk for fracture among patients in our study compared with those in the CANVAS trials. The mean age of our patients was relatively young, we excluded those with a previous fracture, and most did not have osteoporosis; therefore, our findings may not be generalizable to older patients or those with higher baseline risk for fracture.
A concern about null findings in database analyses is that biases arising from misclassification and missing data may shrink the effect size to produce a false null finding. Such an inability to detect known associations (that is, lack of assay sensitivity) can be handled by demonstrating that the data and methods allowed for reproduction of known beneficial or adverse effects (31, 32). The fact that our study design was sensitive enough to detect the known causal association between canagliflozin and a 19% decreased risk for heart failure is therefore reassuring that we could have detected a difference in fracture risk if it were present (26, 33). However, given the upper limit of the CI in our primary analysis (HR, 0.98 [CI, 0.75 to 1.26]), we cannot exclude the possibility of an increased rate of fracture of up to 26%.
Another limitation is that we did not have access to relevant data on diabetes severity (such as duration), risk factors for fracture (such as body mass index and smoking), and other unmeasured confounders (such as race and physical fitness). However, propensity score matching on the other diabetes-related severity and comorbidity variables has been shown to also balance unmeasured characteristics, including diabetes duration, body mass index, and smoking (34).
The primary outcome in CANVAS was low-trauma fractures as determined by the trial adjudication committee. Because our study lacked such detail, we used validated algorithms to identify fractures in claims data, performed a secondary analysis that included other sites of fracture used in the CANVAS trial, and performed a post hoc analysis that excluded patients with a pathologic fracture or fractures related to high-impact trauma.
Finally, there may be overlap of patients between Optum and MarketScan. This means that the CIs for our combined fixed-effects analysis may be slightly narrower than those that would be calculated using a formula that accounts for overlap. A recent pharmacoepidemiologic study of tocilizumab performed an analysis that considered potential overlap between Optum and MarketScan and found that the CIs were slightly wider (at the level of the second decimal point) than those in the analysis that did not consider potential overlap (25) .
In this study of nearly 160 000 propensity scorematched patients with diabetes in the United States, canagliflozin was not associated with increased risk for fracture in routine care. Our results are most relevant to patients with diabetes who do not have other risk factors for fracture, such as older age or previous fracture. These results should be reassuring to patients and physicians who are considering the potential risks and benefits of canagliflozin. Our findings also raise the question of whether the increase in fracture risk reported in CANVAS is limited to patients with high baseline risk. Note: Drs. Fralick and Patorno affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) 
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Birth
Birth begins through broken shells in driven pecks at one's origins or the urgent squeezing thrust from wombs outgrown as perfect home.
Who knows all that it takes to ignite the muscled path or awaken swaddled wings and stir their fluttering?
Who warns of what awaits? the blinding light, the shattering noise the bracing air new lungs must take and boundless space unfolding limbs fall into, flailing.
Warm welcome and soft murmurs cannot change arrival's truththe first proof of longed-for life is its fierce wailing. xx, 403.xx, 404.xx, 572.4x, 791.2x, 791.3x, 274.10, 440.1x, 442.1x, 453.3x, 593.xx, 753.0x, 753.3x, 866.00, 866.01, 866.1x Dementia 290.xx, 294.xx, 330.xx, 331.xx Obesity 278.0x, 649.1, 649.10, 649.11, 649.12, 649.13, 649.14, 649.2, 649.20, 649.21, 649.22, 649.23, 649.24, V85.3x, V85.x, 539 .x or Medication: orlistat, phentermine HCl, phentermine HCl/topiramate, diethylpropion HCl, phendimetrazine tartrate, benzphetamine HCl, sibutramine HCl m-hydrate or HCPCS code: 43644, 43645, 43770, 43842, 43843, 43845, 43846, 43847, 43999 Smoking V15.82, 305.1x, 649.0x, 989.84 or Use of varenicline tartrate or nicotine replacement therapy or CPT/HCPCS code: 99406, 99407, S9075, S9453 Delirium or psychosis 290.11, 290.3x, 290.41, 291.0x, 292.81, 293.xx, 348.3x, 349.82, 290.8x, 290.9x, 295.xx, 297.xx, 298.xx, 299.xx, 780 GLP-1 = glucagon-like peptide-1.
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* Data are numbers (percentages) unless otherwise indicated. † Data were available for 35% of patients in Optum and 6% in MarketScan.
